Partnerships

Built to integrate. Designed to expand what’s possible.

How we work with partners

Harbinger partners with organizations to expand portfolios, accelerate innovation, and unlock new clinical applications.

How
we partner

RESOLVE™ products can address unmet clinical needs, expand use cases, or reach new patient populations—without requiring partners to rebuild their infrastructure.

View from within a high-rise office floor

Innovation pillars

Biology-driven innovation

Harbinger’s partnerships begin with biology focus on early, shared biological programs that emerge at the start of oncogenesis and persist across cancer types and stages. By anchoring innovation in these common biological foundations, partners can pursue solutions that scale across indications without redefining core science.

Enables portfolio expansion across cancers and use cases while maintaining biological coherence.

Science with purpose

Our scientific approach emphasizes rigor, relevance, and restraint. We work with partners to translate biological insight into fit-for-purpose applications, aligning scientific evidence with clearly defined goals.

Reduces technical risk while accelerating meaningful, defensible development.

AI, applied thoughtfully

Harbinger applies machine learning and AI to extract meaningful signal from complex biological data and advanced analytics to improve resolution, scalability, and interpretability. 

Enhances performance and insight without sacrificing transparency or trust.

Platform-enabled collaboration

Harbinger HX is designed to integrate into existing technologies, workflows, and portfolios. Rather than forcing partners into a fixed model, the platform adapts to specific scientific, technical, and commercial needs.

Enables collaboration without disruption, maximizing the value of existing assets while unlocking new applications.

WHO WE WORK WITH

Laboratory and diagnostic companies

To expand test menus, address challenging clinical scenarios, and bring differentiated oncology solutions to market.

Instrument and technology companies

To unlock new applications, demonstrate clinical relevance, and enhance downstream performance of existing platforms.

Data and analytics platforms

To integrate biology-driven signal interpretation with scalable data and AI infrastructure. 

Biopharma partners

To support translational research, biomarker discovery, and development of diagnostics aligned with therapeutic strategies. 